S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,766.69 +1.36%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,766.69 +1.36%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

TVTX

Travere Therapeutics, Inc. TVTX

$56.71 +1.43 (+2.59%)

Neutral · +0.45σ

+ Compare Open in Sniper

News · TVTX

Full news feed →

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

GlobeNewswire Inc. · 1d ago

Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters

The Motley Fool · 69d ago

Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month

GlobeNewswire Inc. · 141d ago

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm

GlobeNewswire Inc. · 168d ago

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

The Motley Fool · 206d ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

GlobeNewswire Inc. · 221d ago

American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions

GlobeNewswire Inc. · 239d ago

10 Health Care Stocks With Whale Alerts In Today's Session

Benzinga · 292d ago

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

GlobeNewswire Inc. · 488d ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 521d ago

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. · 558d ago

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Benzinga · 617d ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

GlobeNewswire Inc. · 630d ago

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Benzinga · 639d ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire Inc. · 642d ago

TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm

GlobeNewswire Inc. · 649d ago

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

GlobeNewswire Inc. · 660d ago

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

GlobeNewswire Inc. · 681d ago

Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?

Zacks Investment Research · 754d ago

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

GlobeNewswire Inc. · 800d ago

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire Inc. · 801d ago

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Zacks Investment Research · 801d ago